TXMD:NASDAQTherapeuticsMD, Inc. Analysis
Data as of 2026-09-01 - not real-time
$2.18
Latest Price
8/10Risk
Risk Level: High
Executive Summary
At $2.18, TherapeuticsMD, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. It has gained 3.3% over the past 30 days. Relative strength is 58.8 — neutral — and the MACD signal is bullish. Price has been bracketed by support at $2.00 and resistance at $2.32.
On valuation the read is undervalued — earnings multiple of 6.2 versus a 30.4 sector average, below the peer group. Revenue is contracting at 8.7% on a -6.6% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 34.7%, a beta of 0.21 and a maximum drawdown of 34.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 3/10 conviction on the long call.
On valuation the read is undervalued — earnings multiple of 6.2 versus a 30.4 sector average, below the peer group. Revenue is contracting at 8.7% on a -6.6% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 34.7%, a beta of 0.21 and a maximum drawdown of 34.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 3/10 conviction on the long call.
Top Market Events
BOCA RATON, Fla. AP — BOCA RATON, Fla. AP — TherapeuticsMD Inc. TXMD on Tuesday reported net income of $155,000 in...MarketWatch1monTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayShares of TherapeuticsMD Inc....MarketWatch26dTherapeuticsMD Inc. stock outperforms competitors on strong trading dayShares of TherapeuticsMD Inc. TXMD...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 2.06
- MACD momentum is positive
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 6.2 versus sector average of 30.4
- Trading above the 200-day average of 2.06
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 6.2 versus sector average of 30.4
- Negative profit margin of -6.6%
- Negative return on equity of -1.1%
Key Metrics & Analysis
Financial Health
Revenue Growth-8.70%
Profit Margin-6.64%
P/E Ratio6.2
ROE-1.08%
ROA-2.88%
Debt/Equity20.49
P/B Ratio0.9
Op. Cash Flow$3.1M
Free Cash Flow$896.6K
Industry P/E30.4
Technical Analysis
TrendBullish
RSI58.8
Support$2.00
Resistance$2.32
MA 20$2.10
MA 50$2.07
MA 200$2.06
MACDBullish
VolumeIncreasing
Fear & Greed Index94.5
Valuation
Fair Value$1.30
GradeUndervalued
TypeValue
Risk Assessment
Beta0.21
Volatility34.75%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.